Skip to main content

Table 3 Rates of conversion from normouricemia at initial check to hyperuricemia and from below common treatment goals to above common treatment goals at any subsequent serum urate check

From: Variation in serum urate levels in the absence of gout and urate lowering therapy

Serum urate at screening (mg/dL) Number of participants Number of participants converted to > 5 Number of participants converted to > 6 Number of participants converted to hyperuricemia (> 6.8 mg/dL)
n % (95% CI) n % (95% CI) n % (95% CI)
4.0–4.4 11 2 18% (2–52%) 0 (0%) 0 (0%)
4.5–4.9 11 5 45%(17–77%) 1 9%(0.2–41%) 1 9%(0.2–41%)
5.0–5.4 14 N/A 6 43%(18–71%) 0 (0%)
5.5–5.9 18 N/A 14 78%(52–94%) 3 17%(4–41%)
6.0–6.8 18 N/A N/A 7 39%(17–64%)
<  5.0 22 7 32%(14–55%) 1 5%(0.1–23%) 1 5%(0.1–23%)
< 6.0 54 N/A 21 39%(26–53%) 4 7%(2–18%)
≤ 6.8 72 N/A N/A 15 21%(12–32%)
  1. mg/dL Milligrams per deciliter